137 related articles for article (PubMed ID: 37955120)
1. Cytoprotective E-WE thrombin reduces disease severity in a murine model of relapsing-remitting multiple sclerosis.
Verbout NG; Su W; Pham P; Jordan KR; Kohs TCL; Tucker EI; McCarty OJT; Sherman LS
Am J Physiol Cell Physiol; 2024 Jan; 326(1):C40-C49. PubMed ID: 37955120
[TBL] [Abstract][Full Text] [Related]
2. E-WE thrombin, a protein C activator, reduces disease severity and spinal cord inflammation in relapsing-remitting murine experimental autoimmune encephalomyelitis.
Verbout NG; Su W; Pham P; Jordan K; Kohs TC; Tucker EI; McCarty OJ; Sherman LS
Res Sq; 2023 Apr; ():. PubMed ID: 37131631
[TBL] [Abstract][Full Text] [Related]
3. Mitoxantrone: a review of its use in multiple sclerosis.
Scott LJ; Figgitt DP
CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
[TBL] [Abstract][Full Text] [Related]
4. Involvement of Degenerating 21.5 kDa Isoform of Myelin Basic Protein in the Pathogenesis of the Relapse in Murine Relapsing-Remitting Experimental Autoimmune Encephalomyelitis and MS Autopsied Brain.
Takano C; Takano T; Masumura M; Nakamura R; Koda S; Bochimoto H; Yoshida S; Bando Y
Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37175866
[TBL] [Abstract][Full Text] [Related]
5. Factor XI as a therapeutic target in neuroinflammatory disease.
Taskin B; Kohs TCL; Shatzel JJ; Puy C; McCarty OJT
Curr Opin Hematol; 2024 Jan; 31(1):32-38. PubMed ID: 37694771
[TBL] [Abstract][Full Text] [Related]
6. Glutathione PEGylated liposomal methylprednisolone (2B3-201) attenuates CNS inflammation and degeneration in murine myelin oligodendrocyte glycoprotein induced experimental autoimmune encephalomyelitis.
Lee DH; Rötger C; Appeldoorn CC; Reijerkerk A; Gladdines W; Gaillard PJ; Linker RA
J Neuroimmunol; 2014 Sep; 274(1-2):96-101. PubMed ID: 25037177
[TBL] [Abstract][Full Text] [Related]
7. NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial.
Sorensen PS; Mellgren SI; Svenningsson A; Elovaara I; Frederiksen JL; Beiske AG; Myhr KM; Søgaard LV; Olsen IC; Sandberg-Wollheim M
Lancet Neurol; 2009 Jun; 8(6):519-29. PubMed ID: 19409854
[TBL] [Abstract][Full Text] [Related]
8. Thrombin mutant W215A/E217A treatment improves neurological outcome and attenuates central nervous system damage in experimental autoimmune encephalomyelitis.
Verbout NG; Yu X; Healy LD; Phillips KG; Tucker EI; Gruber A; McCarty OJ; Offner H
Metab Brain Dis; 2015 Feb; 30(1):57-65. PubMed ID: 24810631
[TBL] [Abstract][Full Text] [Related]
9. Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial.
Ravnborg M; Sørensen PS; Andersson M; Celius EG; Jongen PJ; Elovaara I; Bartholomé E; Constantinescu CS; Beer K; Garde E; Sperling B
Lancet Neurol; 2010 Jul; 9(7):672-80. PubMed ID: 20542736
[TBL] [Abstract][Full Text] [Related]
10. Dynamic changes in meningeal inflammation correspond to clinical exacerbations in a murine model of relapsing-remitting multiple sclerosis.
Walker-Caulfield ME; Hatfield JK; Brown MA
J Neuroimmunol; 2015 Jan; 278():112-22. PubMed ID: 25595260
[TBL] [Abstract][Full Text] [Related]
11. Antibody association with a novel model for primary progressive multiple sclerosis: induction of relapsing-remitting and progressive forms of EAE in H2s mouse strains.
Tsunoda I; Kuang LQ; Theil DJ; Fujinami RS
Brain Pathol; 2000 Jul; 10(3):402-18. PubMed ID: 10885659
[TBL] [Abstract][Full Text] [Related]
12. Mitoxantrone in relapsing-remitting and rapidly progressive multiple sclerosis: Ten-year clinical outcomes post-treatment with mitoxantrone.
Foo EC; Russell M; Lily O; Ford HL
Mult Scler Relat Disord; 2020 Sep; 44():102330. PubMed ID: 32599468
[TBL] [Abstract][Full Text] [Related]
13. Monthly methylprednisolone in combination with interferon beta or glatiramer acetate for relapsing-remitting multiple sclerosis: A multicentre, single-blind, prospective trial.
Ozakbas S; Cinar BP; Kosehasanoğullari G; Kahraman T; Oz D; Kursun BB
Clin Neurol Neurosurg; 2017 Sep; 160():69-72. PubMed ID: 28689102
[TBL] [Abstract][Full Text] [Related]
14. Activated protein C mutant with minimal anticoagulant activity, normal cytoprotective activity, and preservation of thrombin activable fibrinolysis inhibitor-dependent cytoprotective functions.
Mosnier LO; Yang XV; Griffin JH
J Biol Chem; 2007 Nov; 282(45):33022-33. PubMed ID: 17872949
[TBL] [Abstract][Full Text] [Related]
15. The magnitude of the antigen-specific T cell response is separated from the severity of spinal cord histopathology in remitting-relapsing experimental autoimmune encephalomyelitis.
Batoulis H; Uhl M; Addicks K; Lehmann PV; Kuerten S
Glia; 2012 May; 60(5):794-805. PubMed ID: 22319015
[TBL] [Abstract][Full Text] [Related]
16. Rituximab for relapsing-remitting multiple sclerosis.
He D; Guo R; Zhang F; Zhang C; Dong S; Zhou H
Cochrane Database Syst Rev; 2013 Dec; (12):CD009130. PubMed ID: 24310855
[TBL] [Abstract][Full Text] [Related]
17. Experimental models of relapsing-remitting multiple sclerosis: current concepts and perspective.
Skundric DS
Curr Neurovasc Res; 2005 Oct; 2(4):349-62. PubMed ID: 16181126
[TBL] [Abstract][Full Text] [Related]
18. Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-Remitting Multiple Sclerosis.
Koudriavtseva T; Stefanile A; Fiorelli M; Lapucci C; Lorenzano S; Zannino S; Conti L; D'Agosto G; Pimpinelli F; Di Domenico EG; Mandoj C; Giannarelli D; Donzelli S; Blandino G; Salvetti M; Inglese M
Front Immunol; 2020; 11():548604. PubMed ID: 33193314
[TBL] [Abstract][Full Text] [Related]
19. The translocator protein ligand XBD173 improves clinical symptoms and neuropathological markers in the SJL/J mouse model of multiple sclerosis.
Leva G; Klein C; Benyounes J; Hallé F; Bihel F; Collongues N; De Seze J; Mensah-Nyagan AG; Patte-Mensah C
Biochim Biophys Acta Mol Basis Dis; 2017 Dec; 1863(12):3016-3027. PubMed ID: 28899788
[TBL] [Abstract][Full Text] [Related]
20. CD80 (B7-1) and CD86 (B7-2) expression in multiple sclerosis patients: clinical subtype specific variation in peripheral monocytes and B cells and lack of modulation by high dose methylprednisolone.
Boylan MT; Crockard AD; McDonnell GV; Armstrong MA; Hawkins SA
J Neurol Sci; 1999 Aug; 167(2):79-89. PubMed ID: 10521545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
